Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863406 | 0.84 | — | — | |
| SCHEMBL6861913 | 0.83 | GAA (0.34) | TSHRALDH1A1POLBAPEX1HTT | |
| SCHEMBL6856471 | 0.82 | ALDH1A1 (0.42) | TSHRALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6863263 | 0.80 | ALDH1A1 (0.30) | TSHRALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6864649 | 0.77 | LMNA (0.32) | ALDH1A1 | |
| SCHEMBL6863040 | 0.77 | CA1 (0.32) | TSHRALDH1A1POLBAPEX1HTT | |
| SCHEMBL5209650 | 0.75 | ALDH1A1 (0.42) | TSHRALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6863402 | 0.75 | — | — | |
| SCHEMBL6861883 | 0.74 | CA1 (0.46) | TSHRALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6863475 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794471-B2 | OF A HYDROXYHYDROCARBYL- OR MERCAPTOHYDROCARBYL- DITHIOLANE; CURED OPTICAL ARTICLE FORMED BY PHOTOPOLYMERIZING THE ACRYLATE | MITSUI CHEMICALS, INC. (JP) | 2004-09-21 | — | — | US | disclosed |
| EP-1193264-B1 | Acrylic ester compound and usage thereof | MITSUI CHEMICALS INC (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20020061995-A1 | Acrylic ester compound and usage thereof | MITSUI CHEMICALS, INC. (JP) | 2002-05-23 | — | — | US | disclosed |
| EP-1193264-A1 | Acrylic ester compound and usage thereof | Mitsui Chemicals, Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061995-A1 | Acrylic ester compound and usage thereof | ASS1, HAT1, EIF2B1 | TSHR 4411/4885ALDH1A1 132/4885CYP3A4 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.